Contact
Please use this form to send email to PR contact of this press release:
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
TO:
Please use this form to send email to PR contact of this press release:
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
TO: